Last reviewed · How we verify
rIL-21
At a glance
| Generic name | rIL-21 |
|---|---|
| Sponsor | NCIC Clinical Trials Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma (PHASE2)
- Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer (PHASE2)
- Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer (PHASE2)
- Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients (PHASE2)
- Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors (PHASE1)
- Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma (PHASE1)
- Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma (PHASE1, PHASE2)
- Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rIL-21 CI brief — competitive landscape report
- rIL-21 updates RSS · CI watch RSS
- NCIC Clinical Trials Group portfolio CI